Subscribe

What are you looking for?

Main Menu

明報新聞網

中生製藥與勃林格殷格翰達70億美元戰略合作 先獲付款3.58億美元

Future Wealths
Future Wealths
4 11 月, 2026
One Min Read
2 Views
0 Comments
中國生物製藥（1177）公布，與勃林格殷格翰訂立戰略選擇權及許可協議，涵蓋六個涉及抗體偶聯藥物（ADC）及T細胞銜接器（TCE）的臨床前項目，由旗下禮新醫藥及北京泰德提供。

原文: https://finance.mingpao.com/fin/instantf/20261104/1793783530384/%E4%B8%AD%E7%94%9F%E8%A3%BD%E8%97%A5%E8%88%87%E5%8B%83%E6%9E%97%E6%A0%BC%E6%AE%B7%E6%A0%BC%E7%BF%B0%E9%81%9470%E5%84%84%E7%BE%8E%E5%85%83%E6%88%B0%E7%95%A5%E5%90%88%E4%BD%9C-%E5%85%88%E7%8D%B2%E4%BB%98%E6%AC%BE3-58%E5%84%84%E7%BE%8E%E5%85%83%22%20target=%22blank

Last Update: 4 11 月, 2026

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept